GGrantIndex
Sort

261,768 grants matching gene therapy

The role of PKD proteins in regulating tubular morphology

$979,151
Gregory Germino · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK

Multivariate machine learning analysis of blood-based RNA expression profiles to distinguish relapsing-remitting and progressive forms of multiple sclerosis

$979,138
Charles Floyd Spurlock · Decode Health, Inc. · R44 · FY2025 · AI

A Phase III Trial to Validate HP 129Xe MRI as a Functional Pulmonary Biomarker in Pediatric Lung Disease

$979,115
Kiarash Emami · Polarean, Inc. · R44 · FY2019 · HL

From therapeutic mechanisms to unraveling the pathophysiology of MS

$979,095
Bibiana Bielekova · National Institute Of Neurological Disorders And Stroke · ZIA · FY2009 · NS

Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution

$979,093
Michel Mikhail · Trevarx Biomedical, Inc. · R42 · FY2024 · CA

A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed

$979,050
Maria Constance Athanasiou · Marpam Pharma, Llc · R42 · FY2025 · AI

A Mechanistic and Translational Research Program Linking Impaired Resolution, Defective Efferocytosis, and Clonal Hematopoiesis to the Formation of Clinically Dangerous Atherosclerotic Plaques

$979,027
Ira A Tabas · Columbia University Health Sciences · R35 · FY2020 · HL

Functional Mechanisms of T1D Risk Variants and their Target Genes using 3D Epigenomics and Single Cell Approaches

$979,027
Stephen S. Rich · University Of Virginia · R01 · FY2021 · DK

Automated Systems for Detection and Molecular Characterization of Circulating Tum

$979,021
Yuling Luo · Advanced Cell Diagnostics, Inc. · R44 · FY2012 · CA

Molecular Mechanisms of the Blood Brain Barrier Function and Regulation

$979,016
Chenghua Gu · Harvard Medical School · R35 · FY2024 · NS

Capacity Enhancement Core

$978,952
Patricia Chamberlain · Oregon Social Learning Center, Inc. · P30 · FY2009 · DA

Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level

$978,890
Andrea Califano · Columbia University Health Sciences · R35 · FY2025 · CA

Maturation of Human Lymphocytes for Transplantation

$978,822
Gerald J Spangrude · University Of Utah · RC1 · FY2010 · AI

A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance

$978,755
Neil A Fanger · Virtici, Llc · R44 · FY2023 · AI

Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB

$978,349
Rhea N Coler · Seattle Children'S Hospital · R01 · FY2025 · AI

Severe Chronic Neutropenia International Registry

$978,341
David Chandler Dale · University Of Washington · R24 · FY2017 · AI

Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB

$978,338
Rhea N Coler · Seattle Children'S Hospital · R01 · FY2024 · AI

Reversal of HIV latency in vivo

$978,330
Steven Grant Deeks · University Of California, San Francisco · U19 · FY2014 · AI

Identification of Gene Polymorphisms Associated with Infectious Diseases

$978,326
Cheryl Winkler · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Program Project Grant: Bone Cell Structue and Gene Expression

$978,198
Gary S. Stein · Univ Of Massachusetts Med Sch Worcester · P01 · FY2008 · AR

Modeling Combination Immunotherapy for HIV Cure in Humanized Mouse Models

$978,174
James L Riley · University Of Pennsylvania · U19 · FY2021 · AI

Rapid 3D POC digital cancer pathology by unique confocal microscopy instrumentation and downstream AI: a simple, efficient, robust direct-to-digital approach to meet market demand

$978,154
Daniel Summer Gareau · Surgivance, Inc. · R44 · FY2025 · CA

Tumor stem cells and metastatic outcomes in mouse models of prostate cancer

$978,122
Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

THE PHARMACODYNAMICS OF GENES AND OLIGONUCLEOTIDES

$978,093
University Of North Carolina Chapel Hill · P01 · FY2000 · GM

Oral anti-TNF antibody for inflammatory bowel disease

$978,045
Daniel E Tracey · Avaxia Biologics, Inc. · R44 · FY2012 · DK